In the last trading session, 4.1 million shares of the 10x Genomics Inc (NASDAQ:TXG) were traded, and its beta was 2.02. Most recently the company’s share price was $11.92, and it changed around -$1.09 or -8.38% from the last close, which brings the market valuation of the company to $1.49B. TXG currently trades at a discount to its 52-week high of $24.76, offering almost -107.72% off that amount. The share price’s 52-week low was $6.78, which indicates that the current value has risen by an impressive 43.12% since then. We note from 10x Genomics Inc’s average daily trading volume that its 10-day average is 5.2 million shares, with the 3-month average coming to 4.13 million.
10x Genomics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.32. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 9 recommended TXG as a Hold, whereas 5 deemed it a Buy, and 1 rated it as Underweight.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG has showed a red trend with a performance of -8.38% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 13.14 on recent trading dayincreased the stock’s daily price by 9.28%. The company’s shares are currently down -36.83% year-to-date, but still up 1.62% over the last five days. On the other hand, 10x Genomics Inc (NASDAQ:TXG) is 27.62% up in the 30-day period. We can see from the shorts that 13.43 million shares have been sold at a short interest cover period of 3.59 day(s).
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 52.32% from its current value. Analyst projections state that TXG is forecast to be at a low of $24 and a high of $46.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -36.10%. 10x Genomics Inc earnings are expected to increase by 19.08% in 2025, but the outlook is positive 24.74% per year for the next five years.
TXG Dividends
10x Genomics Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.93% of 10x Genomics Inc shares, and 101.63% of them are in the hands of institutional investors. The stock currently has a share float of 103.63%. 10x Genomics Inc stock is held by 372.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 10.836% of the shares, which is about 13.01 million shares worth $253.05 million.
VANGUARD GROUP INC, with 8.4863% or 10.19 million shares worth $198.18 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
